|
Biomind Labs to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
|
|
Biomind Labs Inc
|
Nov 11, 2021 08:00AM
|
|
Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022
|
|
Biomind Labs Inc
|
Mar 30, 2022 08:37AM
|
|
Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London
|
|
Biomind Labs Inc
|
Apr 12, 2022 07:25AM
|
|
Biomind Labs to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
|
|
Biomind Labs Inc
|
Dec 02, 2021 07:45AM
|
|
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
|
|
Biomind Labs Inc
|
Mar 24, 2022 08:10AM
|
|
Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London
|
|
Biomind Labs Inc
|
May 09, 2022 07:20AM
|
|
Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate…
|
|
Biomind Labs Inc
|
May 26, 2022 07:25AM
|
|
Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression
|
|
Biomind Labs Inc
|
Mar 09, 2022 07:25AM
|
|
Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax™
|
|
Biomind Labs Inc
|
Mar 31, 2023 07:25AM
|
|
Biomind Labs Opens a New Clinical Psychedelic Research Facility
|
|
Biomind Labs Inc
|
Mar 17, 2022 07:25AM
|
|
Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application
|
|
Biomind Labs Inc
|
Aug 12, 2021 09:00AM
|
|
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based...
|
|
Biomind Labs Inc
|
Apr 26, 2022 08:38AM
|
|
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
|
|
Biomind Labs Inc
|
Sep 14, 2023 10:48AM
|
|
Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form
|
|
Biomind Labs Inc
|
Nov 18, 2021 07:45AM
|
|
Biomind Labs Begins Trading on the NEO Exchange
|
|
Biomind Labs Inc
|
Jul 28, 2021 08:00AM
|
|
Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States
|
|
Biomind Labs Inc
|
Feb 17, 2022 07:30AM
|
|
Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease…
|
|
Biomind Labs Inc
|
Apr 25, 2023 10:32AM
|
|
Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety…
|
|
Biomind Labs Inc
|
Dec 28, 2022 09:22AM
|
|
Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression
|
|
Biomind Labs Inc
|
Oct 11, 2022 12:38PM
|
|
Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07
|
|
Biomind Labs Inc
|
Mar 03, 2022 07:30AM
|
